Loading organizations...
Transcept Pharmaceuticals developed enhanced formulations of established central nervous system (CNS) medications. Its primary product, Intermezzo, was a fast-acting sublingual lozenge with a low-dose zolpidem formulation, delivered via proprietary Bimucoral technology for middle-of-the-night insomnia. The company also developed TO-2060, a fixed combination product aimed at treating alcohol dependence and related psychiatric disorders.
Founded in 2001 by Nikhilesh Singh and Tom Soloway, Transcept’s core insight was that significant patient benefits derived from innovating the delivery of existing CNS compounds. This strategy focused on modifying proven active agents to create therapeutic advantages, addressing unmet medical needs through improved formulations.
Transcept’s products served patients with specific sleep disturbances, particularly those waking during the night, and individuals seeking improved treatments for alcohol dependence. The company envisioned itself as an evolving specialty pharmaceutical leader, dedicated to commercializing proprietary solutions offering tangible advancements in patient care within psychiatry and sleep medicine.
Transcept Pharmaceuticals has raised $40.0M across 1 funding round.
Transcept Pharmaceuticals has raised $40.0M in total across 1 funding round.
Transcept Pharmaceuticals is a specialty pharmaceutical company, not a technology company in the typical tech startup sense, focused on developing and commercializing proprietary products for neuroscience, particularly in psychiatry and sleep medicine.[1][2][3] It addressed unmet therapeutic needs in these areas, serving patients with neurological and mental health conditions through targeted drug development.[2][3] The company was publicly traded and operated in the healthcare and life sciences sectors, with some classifications placing it under chemicals and plastics due to pharmaceutical manufacturing.[3][4]
While specific growth metrics are limited in available data, Transcept gained traction as a portfolio company of investors like NEA, indicating early promise in biotech innovation before its trajectory shifted.[3]
Transcept Pharmaceuticals emerged as a biotech-focused entity specializing in neuroscience therapeutics, though exact founding details and founders are not detailed in current records.[1][2] It built early momentum through development pipelines targeting psychiatry and sleep disorders, attracting investment from prominent venture firms like NEA in the healthcare space.[3] Pivotal moments included advancing proprietary products to commercialization stages, positioning it as a player in specialty pharma amid growing demand for neuroscience treatments.[1][2]
The company evolved from R&D-centric operations to public markets, reflecting a classic biotech path of scaling innovations for broader therapeutic impact.[4]
Transcept rode the wave of neuroscience and biotech innovation in the 2000s-2010s, when advances in CNS drug discovery aligned with rising mental health awareness and sleep disorder prevalence.[2][3] Timing mattered as regulatory shifts and investor interest in life sciences amplified opportunities for specialty pharma amid stagnant big pharma pipelines.[1] Market forces like aging populations and neuroscience research breakthroughs favored its model, influencing the ecosystem by exemplifying how VC-backed biotechs could bridge R&D to market.[3]
It contributed to the broader biotech landscape by highlighting scalable models for niche therapeutics, paving ways for subsequent players in psychiatry-focused innovation.
Transcept's story underscores biotech's high-stakes pivot from promise to market realities, with its public status enabling growth but exposing it to sector volatilities.[4] Looking ahead, trends like precision neuroscience and AI-driven drug discovery could revive similar models, though Transcept itself appears historical rather than active today. Its influence may evolve through alumni networks or IP legacies shaping modern CNS therapies—watch for echoes in today's mental health biotech boom, tying back to its core mission of proprietary neuroscience solutions.[1][2]
Transcept Pharmaceuticals has raised $40.0M across 1 funding round. Most recently, it raised $40.0M Series D in March 2007.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 1, 2007 | $40M Series D | — | SR ONE | Announced |
Transcept Pharmaceuticals has raised $40.0M in total across 1 funding round.
Transcept Pharmaceuticals's investors include SR One Capital Management.
